# PT-141 Research: Mechanism, the RECONNECT Trials, and the Off-Label Male Data

> PT-141 acts centrally on melanocortin MC4R/MC3R circuits, not on blood flow. The RECONNECT Phase 3 results, the fMRI mechanism data, and the off-label male research, cited.

How the molecule works in the brain, what the RECONNECT trials actually met, and why the off-label male data stays investigational.

## The short version

Here is the PT-141 research in plain terms. The molecule works on the brain's desire circuitry, not on blood flow — that is the one thing nearly every study agrees on [1]. In two big trials of premenopausal women with HSDD, it beat placebo on two scores: how much desire women felt, and how much distress their low desire caused [3]. The win was statistically real but small, and some independent reviewers argue it is too small to matter much. In men, the erectile research is early-stage and was never approved. The cited detail follows.

## What is a melanocortin receptor agonist?

A melanocortin receptor agonist is a compound that switches on one or more of the five melanocortin receptors (MC1R-MC5R) — the receptors that normally respond to peptides such as alpha-MSH [1]. PT-141 is a synthetic analogue of alpha-MSH that targets the central nervous-system subtypes, MC3R and MC4R [1]. The five receptors do different jobs: MC1R sits in the skin and governs pigment; MC4R sits in brain circuits that govern desire and appetite. That single fact explains why a drug aimed at desire can also change skin color and appetite — it is the same receptor family, in different tissues. Bremelanotide belongs to this MC3R/MC4R class, alongside the related peptides surveyed in the melanocortin sexual-medicine literature [9].

## PT-141 mechanism of action

PT-141's mechanism of action is central, not peripheral. It activates melanocortin receptors — chiefly MC4R, secondarily MC3R — concentrated in the hypothalamus and limbic system [1]. By stimulating MC4R in circuits such as the medial preoptic area (a hypothalamic region tied to sexual motivation), it is thought to engage dopamine pathways that drive appetitive, desire-led sexual behavior [1][8]. This is mechanistically distinct from PDE-5 inhibitors (sildenafil, tadalafil), which act peripherally on vascular smooth muscle to improve erectile blood flow. PT-141 does not act on blood flow and does not act through the HPG axis; it does not directly raise testosterone. The earliest pharmacology showed the central signature directly: in rats and nonhuman primates, systemic PT-141 produced erections and lit up hypothalamic neurons (increased c-Fos), and in men with erectile dysfunction it produced rapid, dose-dependent erectile activity [1].

## How does PT-141 work?

PT-141 works by activating central melanocortin receptors, chiefly MC4R, in the hypothalamus and limbic system [1]. Stimulating MC4R in motivation circuits engages dopaminergic signaling for appetitive sexual behavior — a brain mechanism, not a blood-flow one [1][8]. Mechanistic imaging supports this: in a crossover fMRI study of 31 premenopausal women with HSDD, MC4R agonism increased sexual desire for up to 24 hours and altered how the brain processed erotic stimuli, including enhanced amygdala-insula functional connectivity [5].

## Does PT-141 work through the brain or through blood flow?

Through the brain. PT-141 acts centrally on melanocortin circuits that govern sexual motivation — distinct from PDE-5 inhibitors, which act peripherally on vascular smooth muscle to improve blood flow [1]. The crossover fMRI work in women with HSDD is the clearest human evidence of a central action: MC4R agonism altered task-based brain processing of erotic stimuli rather than changing peripheral circulation [5].

## What the research shows PT-141 does

The strongest evidence for PT-141 benefits is in premenopausal women with HSDD. In two identical Phase 3 trials (RECONNECT, n=1267), bremelanotide 1.75 mg subcutaneous as-needed met both coprimary endpoints over 24 weeks: a statistically significant gain in sexual desire (integrated FSFI-desire +0.35, P<.001) and a reduction in desire-related distress (integrated FSDS-DAO item 13 -0.33, P<.001) versus placebo [3]. (FSFI and FSDS-DAO are the standard questionnaires trials use to score sexual desire and the distress low desire causes.) Keep the framing honest: the effect is statistically real but clinically modest, and independent re-analyses (Spielmans 2021, 2024) have argued the gains are small and questioned the outcome measures. The mechanism was traced earlier in animals — in female rats, PT-141 selectively increased solicitational (desire-driven) behavior without affecting reflexive responses, making it the first agent reported to act on appetitive female sexual behavior [2].

## What were the results of the PT-141 clinical trials?

Two identical Phase 3 RCTs (RECONNECT, n=1267 premenopausal women with HSDD) found bremelanotide 1.75 mg subcutaneous as-needed met both coprimary endpoints over 24 weeks [3]. A 52-week open-label extension (684 women enrolled) sustained the desire improvement with no new safety signals; the most common drug-related events were nausea (40.4%), flushing (20.6%), and headache (12.0%) [4]. Dose selection traced back to a randomized dose-finding trial (0.75, 1.25, 1.75 mg) and a Phase 2b responder analysis that together supported the 1.75 mg dose advanced to Phase 3 [10][11].

## What receptors does PT-141 act on?

Primarily the melanocortin 4 receptor (MC4R) and, secondarily, the melanocortin 3 receptor (MC3R) — both central-nervous-system subtypes [1]. A third receptor matters for the side effects rather than the benefit: MC1R activation in the skin accounts for the hyperpigmentation seen with repeated dosing [4].

## How is PT-141 different from PDE-5 inhibitors?

PDE-5 inhibitors (sildenafil, tadalafil) act peripherally on vascular smooth muscle to improve erectile blood flow [1]. PT-141 acts centrally on melanocortin circuits that govern sexual desire and arousal — a different target and a different mechanism. The two are not interchangeable: one addresses the plumbing of an erection, the other the brain's desire signal.

## PT-141 for men: off-label and investigational

Use of PT-141 for men is off-label and investigational — it is not an approved use, and the evidence is early-phase only. The earliest human pharmacology did show rapid, dose-dependent erectile activity in men with erectile dysfunction, consistent with the central mechanism [1], and early intranasal research escalated doses to roughly 7-20 mg, reporting a statistically significant erectile response above 7 mg [7]. But the intranasal route was discontinued for pharmacokinetic variability, and no male indication was ever approved. One historical erectile-dysfunction study (Safarinejad & Hosseini, 2008) received a 2023 Expression of Concern and should be treated as disputed. Current male-ED development is a combination-with-a-PDE-5-inhibitor Phase 2 program — investigational, not established. Treat all male use as research, never as a settled therapy.

## What a recent negative finding adds

Not every new study reinforces the desire story, and an honest record includes the nuanced ones. A 2025 study in female Syrian hamsters found that MC3R/MC4R messenger RNA was concentrated in dopamine neurons of the ventral tegmental area, but neither low- nor high-dose bremelanotide changed melanocortin-receptor expression in the mesolimbic dopamine system, and bremelanotide did not enhance sexual reward in a conditioned place-preference test [12]. The authors read this as evidence that, in that model, the drug does not act on the brain's reward circuit — a careful, partly-negative result that sits alongside the positive human imaging work [5][12].

---

PT-141 read as a raw instrument of record — the one approved use, the modest effect, and the nausea-led tolerability cost ruled into the page and cited line by line, with the unverified field reports fenced off behind a dashed border; no clinic behind the grid and nothing here dosed, sourced, or sold.